The β-adrenergic agonists salbutamol and ephedrine have been well established for the therapy of congenital myasthenic syndromes with AGRN, COLQ, DOK7, LRP4 and MUSK mutations (132, 133), but with only anecdotal clinical experience of salbutamol in MuSK-MG (134, 135). The gene discussed is MUSK; the disease is congenital myasthenic syndrome.